Table 5. Diagnostic test performances of the CareStart G6PD RDT by gender, according to the cut-off values used to define G6PDd, Pailin, Cambodia, 2013.

Cut-off values	in %	<10%	<20%	<30%	<40%	<50%	<60%	≥60%
	in UI/g Hg	<1.2	<2.4	<3.6	<4.8	<6.0	<7.2	≥7.2
Males
No. of samples classified as G6PD deficient according to the cut-off value		48	57	59	59	59	59	392
CareStart G6PD RDT	No. of males classified as deficient/intermediate	48	57	59	59	59	59	5
	No. of males classified as normal	0	0	0	0	0	0	387
	Sensitivity (95% CI)	100% (92.6–100%)	100% (93.7–100%)	100% (93.9–100%)	100% (93.9–100%)	100% (93.9–100%)	100% (93.9–100%)
	Specificity (95% CI)	96.0% (93.6–97.7%)	98.2% (96.3–99.3%)	98.7% (97.1–99.6%)	98.7% (97.1–99.6%)	98.7% (97.1–99.6%)	98.7% (97.1–99.6%)
	Deficiency status Predictive Value - PPV (95% CI)	75.0% (62.6–85.0%)	89.1% (78.7–95.5%)	92.2% (82.7–97.4%)	92.2% (82.7–97.4%)	92.2% (82.7–97.4%)	92.2% (82.7–97.4%)
	Normal status Predictive Value - NPV (95% CI)	100% (99.1–100%)	100% (99.1–100%)	100% (99.1–100%)	100% (99.1–100%)	100% (99.1–100%)	100% (99.1–100%)
Females
No. of samples classified as G6PD deficient according to the cut-off value (%)		8	11	15	30	48	68	419
CareStart G6PD RDT	No. of females classified as deficient/intermediate	8	11	15	24	29	32	9
	No. of females classified as normal	0	0	0	6	19	36	410
	Sensitivity (95% CI)	100% (63.1–100%)	100% (71.5–100%)	100% (78.2–100%)	80.0% (61.4–92.3%)	60.4% (45.3–74.2%)	47.0% (34.6–59.6%)
	Specificity (95% CI)	93.1% (90.4–95.2%)	95.5% (93.2–97.2%)	94.5% (92.0–96.4%)	96.2% (96.5–99.2%)	97.3% (95.3–98.6%)	97.9% (95.9–99.0%)
	Deficiency status Predictive Value - PPV (95% CI)	19.1% (8.8–34.9%)	34.4% (18.6–53.2%)	36.6% (22.1–53.1%)	75.0% (56.6–88.5%)	70.7% (54.5–83.9%)	78.0% (62.4–89.4%)
	Normal status Predictive Value - NPV (95% CI)	100% (99.2–100%)	100% (99.2–100%)	100% (99.2–100%)	98.6% (97.1–99.5%)	95.7% (93.4–97.4%)	91.9% (89.0–94.3%)